Genetically Engineered Biomimetic Nanovesicles Co-Deliveing a Checkpoint Inhibitor and Doxorubicin for Enhanced Cancer Chemo-Immunotherapy
Pharmaceutics · 26.01.2026 · 18 (2) · 159
DOI: 10.3390/pharmaceutics18020159 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 26.01.2026. Verfasst von Yunying Xing und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Food Science and Biology, Hebei University of Science and Technology, Shijiazhuang 050000, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebei University of Science and Technology Startup Fund, National Natural Science Foundation of China, Science Foundation for Post Doctorate Research of the Ministry of Science and Technology of China.
Abstract (Originalsprache)
Background/Objectives: Despite the clinical success of immune checkpoint blockade (ICB), its efficacy remains limited in immunologically “cold” tumors, primarily due to poor immunogenicity and an immunosuppressive tumor microenvironment (TME). Chemo-immunotherapy offers a potential strategy to enhance ICB response, yet its application is often hindered by inadequate tumor-targeted delivery and systemic immunosuppressive side effects. Biomimetic nanotechnology represents a promising approach to overcoming these limitations by improving drug delivery and facilitating effective combination regimens.
Methods
We developed a biomimetic nanosystem (NVs@DOX) through genetic engineering of cellular membranes and optimized nanoformulation techniques, enabling co-delivery of doxorubicin (DOX) and ICB agents. This design aims to maximize synergistic antitumor effects while minimizing adverse impacts.
Results
In vitro studies demonstrated the potent cytotoxicity of NVs@DOX, including significant inhibition of cancer cell proliferation and complete suppression of colony formation. In a 4T1 murine breast cancer model, NVs@DOX treatment led to substantial tumor growth inhibition (approximately 72%) without notable body weight loss, underscoring a favorable safety profile alongside enhanced therapeutic efficacy.
Conclusions
The NVs@DOX platform effectively integrates doxorubicin with ICB within a biomimetic nanocarrier, significantly improving chemo-immunotherapy outcomes. This strategy highlights the potential of genetically engineered cellular nanoparticles as a promising combinatorial approach for the treatment of breast cancer.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Food Science and Biology, Hebei University of Science and Technology, Shijiazhuang 050000, China.
- Aier Glaucoma Institute, Hunan Engineering Research Center for Glaucoma with Artificial Intelligence in Diagnosis and Application of New Materials, Changsha Glaucoma Diagnosis and Treatment Technology Innovation Center,…
- State Key Laboratory of Medical Proteomics, National Center for Protein Sciences at Beijing, Beijing Proteome Research Center, Beijing Institute of Radiation Medicine, Beijing 100000, China.
ORCID-Profile: Xinyi Liu, Yingze Wang, Wenxiang Zhu
Förderung
- Hebei University of Science and Technology Startup Fund
- National Natural Science Foundation of China
- Science Foundation for Post Doctorate Research of the Ministry of Science and Technology of China
- Changsha Municipal Natural Science Foundation of China
- Shijiazhuang Key Special Project for Biomedicine Technology Innovation
- Beijing Natural Science Foundation
Zitieren
APA
Xing, Y., Liu, X., Wang, Z., Wang, Y., Zhang, J., & Zhu, W. (2026). Genetically Engineered Biomimetic Nanovesicles Co-Deliveing a Checkpoint Inhibitor and Doxorubicin for Enhanced Cancer Chemo-Immunotherapy. Pharmaceutics, 18(2), 159. https://doi.org/10.3390/pharmaceutics18020159
Vancouver
Xing Y, Liu X, Wang Z, Wang Y, Zhang J, Zhu W. Genetically Engineered Biomimetic Nanovesicles Co-Deliveing a Checkpoint Inhibitor and Doxorubicin for Enhanced Cancer Chemo-Immunotherapy. Pharmaceutics. 2026;18(2):159. doi:10.3390/pharmaceutics18020159
BibTeX
@article{Xing2026,
author = {Xing, Yunying and Liu, Xinyi and Wang, Zhenkun and Wang, Yingze and Zhang, Jing and Zhu, Wenxiang},
title = {Genetically Engineered Biomimetic Nanovesicles Co-Deliveing a Checkpoint Inhibitor and Doxorubicin for Enhanced Cancer Chemo-Immunotherapy},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {2},
pages = {159},
doi = {10.3390/pharmaceutics18020159}
}
EUVIMED